Inclusion Criteria:
- Diagnosis of discoid/subacute cutaneous lupus erythematosus (DLE/SCLE) for at least 3
months prior to screening visit
- Meets both clinical and histopathological diagnostic cutaneous lupus erythematosus
(CLE) criteria per protocol
- Currently receiving treatment for DLE/SCLE with a stable regimen of at least one of
the following medications: oral corticosteroid, and/or antimalarial, and/or
immunosuppressant
- Participant could be with or without concurrent systemic lupus erythematosus (SLE)
- If participant receives nonsteroidal anti-inflammatory drugs (NSAIDs) or analgesics
treatment then the participant must be on a stable dose 2 weeks prior to screening
Exclusion Criteria:
- Women who are pregnant, lactating, breastfeeding or planning pregnancy during the
study period
- Any of the following specific CLE subtypes in isolation: acute cutaneous lupus
erythematosus (ACLE), lupus tumidus, lupus (profundus) panniculitis, chilblains
- Drug-induced CLE and/or drug-induced systemic lupus erythematosus (SLE)
- Antiphospholipid antibody syndrome, serious thrombotic event or unexplained pregnancy
loss within 1 year before the screening visit
- History of 3 or more unexplained consecutive pregnancy losses
- Active severe or unstable neuropsychiatric SLE
- Other autoimmune diseases or non-SLE driven inflammatory joint or skin disease or
overlap syndromes as primary disease that in the opinion of the investigator will
significantly impact the assessment of CLE/SLE disease manifestations and activity
Other protocol-defined inclusion/exclusion criteria apply
Recruiting
